

## **In-situ surface functionalization of superparamagnetic reduced graphene oxide – Fe<sub>3</sub>O<sub>4</sub> nanocomposite via *Ganoderma lucidum* extract for targeted cancer therapy application**

### **ABSTRACT**

A superparamagnetic graphene-based magnetite nanocomposite (rGO-Fe<sub>3</sub>O<sub>4</sub>) was synthesized via a simple in-situ chemical approach. This rGO-Fe<sub>3</sub>O<sub>4</sub> nanocomposite can be used as a drug carrier that is able to be guided by external magnetic fields to the specific site of interest for targeted drug delivery application to treat cancer. *Ganoderma lucidum* extract (GL) was employed, which successfully stabilized the rGO-Fe<sub>3</sub>O<sub>4</sub> via hydrogen bonding and resulted in enhancement of water dispersibility and stability of the prepared nanocomposite, while Pluronic F-127 (PF) was introduced to reduce the overall cytotoxicity. The presence of both GL and PF on the surface of nanocomposite was successfully validated by cyclic voltammetry (CV). Quercetin (Que), a naturally-available polyphenolic flavonoid with anti-cancer properties was utilized to study the potential of rGO-Fe<sub>3</sub>O<sub>4</sub>-GL-PF for controlled drug delivery application. The loading capacity of Que on rGO-Fe<sub>3</sub>O<sub>4</sub>-GL-PF was determined to be 11 wt% through UV–visible spectroscopy. The Que was loaded on rGO plane via  $\pi$ - $\pi$  stacking and hydrophobic interaction, which was validated through CV. Furthermore, the in-vitro cytotoxicity of the synthesized nanocomposite showed obvious cytotoxicity toward A549 cells due to the anti-cancer properties of GL which has high potential to be developed into a targeted drug delivery carrier for cancer therapeutics.

**Keyword:** Superparamagnetic rGO-Fe<sub>3</sub>O<sub>4</sub> nanocomposite; *Ganoderma lucidum*; Drug carrier; Quercetin; Cancer therapy